Oppenheimer downgrades Insulet’s stock rating, citing increasing concerns about the company’s diabetes-related growth. Seeking Alpha reports the downgrade is driven by what it describes as growing risks, while Investing.com similarly characterizes the move as reflecting worries about Insulet’s ability to maintain momentum in the diabetes market. The outlets do not provide detailed operational findings in the excerpts provided, but both sources frame the rating change as a response to uncertainty around the pace and durability of diabetes growth. Overall, the reporting indicates that Oppenheimer’s reassessment leads to a lower investment rating for Insulet, reflecting a more cautious view of future performance tied to its diabetes business. No additional company-specific updates, financial figures, or new guidance are included in the information shared here, and neither outlet’s snippet specifies the magnitude of the downgrade or the target price. The key shared point is that Oppenheimer lowers its rating due to concerns about diabetes growth prospects and associated risks.